TABLE OF CONTENTS

1           Introduction

1.1   Market Definition

1.2   Market Scope

2           Research Methodology

2.1   Primary Research

2.2   Research Methodology

2.3   Assumptions & Exclusions

2.4   Secondary Data Sources

3           Market Overview

3.1   Report Segmentation & Scope

3.2   Value Chain Analysis: Cancer Treatment Market

3.3   Key Market Trends

3.3.1    Drivers

3.3.2    Restraints

3.3.3    Opportunities

3.4   Porter’s Five Forces Analysis

3.4.1    Bargaining Power of Suppliers

3.4.2    Bargaining Power of Buyers

3.4.3    Threat of Substitution

3.4.4    Threat of New Entrants

3.4.5    Competitive Rivalry

3.5   Market Share Analysis

3.6    Top Selling Chemotherapy Drugs, 2017, USD Million

3.7     Top selling cancer drugs, 2018, USD Million

4           By Application Overview

4.1   Introduction

4.1.1    Market Size & Forecast (Value)

4.2   Blood Cancer

4.3   Lung Cancer

4.4   Colorectal Cancer

4.5   Prostate Cancer

4.6   Breast Cancer

4.7   Cervical Cancer

4.8   Others

5           By Therapy Overview

5.1   Introduction

5.1.1    Market Size & Forecast (Value)

5.2   Chemotherapy

5.3   Targeted Therapy

5.4   Immunotherapy

5.5   Hormonal Therapy

5.6   Others

6           End Users

6.1   Introduction

6.1.1    Market Size & Forecast (Value)

6.2   Hospitals

6.3   Specialty Clinics

6.4   Cancer & Radiation Therapy Centres

7            Regional Overview

7.1        Introduction

7.1.1    Market Size & Forecast (Value)

7.2        America

7.2.1    North America

7.2.1.1   U.S.

7.2.1.1.1 By Treatment

7.2.1.1.2 By Therapy

7.2.1.1.3 By End Users

7.2.1.2   Canada

7.2.1.2.1 By Treatment

7.2.1.2.2 By Therapy

7.2.1.2.3 By End Users

7.2.1.3   Mexico

7.2.1.3.1 By Treatment

7.2.1.3.2 By Therapy

7.2.1.3.3 By End Users

7.2.2    Latin America

7.2.2.1   By Treatment

7.2.2.2   By Therapy

7.2.2.3   By End Users

7.3        Europe

7.3.1    Market Size & Forecast (Value)

7.3.2    Germany

7.3.2.1   By Treatment

7.2.2.2   By Therapy

7.3.2.3   By End Users

7.3.3    France

7.3.3.1   By Treatment

7.3.3.2   By Therapy

7.3.3.3   By End Users

7.3.4    U.K.

7.3.4.1   By Treatment

7.3.4.2   By Therapy

7.3.4.3   By End Users

7.3.5    Italy

7.3.5.1   By Treatment

7.3.5.2   By Therapy

7.3.5.3   By End Users

7.3.6    Spain

7.3.6.1   By Treatment

7.3.6.2   By Therapy

7.3.6.3   By End Users

7.3.7    Rest of Europe

7.3.7.1   By Treatment

7.3.7.2   By Therapy

7.3.7.3   By End Users

7.4         Asia-Pacific

7.4.1    Market Size & Forecast (Value)

7.4.2    Japan

7.4.2.1   By Treatment

7.4.2.2   By Therapy

7.4.2.3   By End Users

7.4.3    China

7.4.3.1   By Treatment

7.4.3.2   By Therapy

7.4.3.3   By End Users

7.4.4    Australia

7.4.4.1   By Treatment

7.4.4.2   By Therapy

7.4.4.3   By End Users

7.4.5    India

7.4.5.1   By Treatment

7.4.5.2   By Therapy

7.4.5.3   By End Users

7.4.6    South Korea

7.4.6.1   By Treatment

7.4.6.2   By Therapy

7.4.6.3   By End Users

7.4.7    Rest of Asia-Pacific

7.4.7.1   By Treatment

7.4.7.2   By Therapy

7.4.7.3   By End Users

7.5        Middle East & Africa

7.5.1    Market Size & Forecast (Value)

7.5.2    Saudi Arabia

7.5.2.1   By Treatment

7.5.2.2   By Therapy

7.5.2.3   By End Users

7.5.3    South Africa

7.5.3.1   By Treatment

7.3.3.2   By Therapy

7.5.3.3   By End Users

7.5.4    Kuwait

7.5.4.1   By Treatment

7.5.4.2   By Therapy

7.5.4.3   By End Users

7.5.5    Rest of Middle East & Africa

7.5.5.1   By Treatment

7.5.5.2   By Therapy

7.5.5.3   By End Users

8.          Company Profile 

8.1        F. Hoffmann-La Roche AG

8.1.1    Company Overview

8.1.2    Financial Performance

8.1.3    Recent Developments

8.1.4    Product Portfolio

8.2        Bristol-Myers Squibb Company

8.2.1    Company Overview

8.2.2    Financial Performance

8.2.3    Recent Developments

8.2.4   Product Portfolio

8.3        AbbVie, Inc.

8.3.1    Company Overview

8.3.2    Financial Performance

8.3.3    Recent Developments

8.3.4    Product Portfolio

8.4        Johnson & Johnson

8.4.1    Company Overview

8.4.2    Financial Performance

8.4.3    Recent Developments

8.4.4    Product Portfolio

8.5         Celgene Corporation

8.5.1    Company Overview

8.5.2    Financial Performance

8.5.3    Recent Developments

8.5.4    Product Portfolio

8.6         Astellas Pharma, Inc.

8.6.1    Company Overview

8.6.2    Financial Performance

8.6.3    Recent Developments

8.6.4    Product Portfolio

8.7         Pfizer, Inc.

8.7.1    Company Overview

8.7.2    Financial Performance

8.7.3    Recent Developments

8.7.4    Product Portfolio

8.8        Novartis AG

8.8.1    Company Overview

8.8.2    Financial Performance

8.8.3    Recent Developments

8.8.4    Product Portfolio

8.9       Merck KGaA     

8.9.1    Company Overview

8.9.2    Financial Performance

8.9.3    Recent Developments

8.9.4    Product Portfolio

8.10     Eli Lilly, AstraZeneca plc 

8.10.1    Company Overview

8.10.2    Financial Performance

8.10.3    Recent Developments

8.10.4    Product Portfolio

8.11     Bayer AG   

8.11.1    Company Overview

8.11.2    Financial Performance

8.11.3    Recent Developments

8.11.4    Product Portfolio

8.12     Takeda Pharmaceutical Company Limited.    

8.12.1    Company Overview

8.12.2    Financial Performance

8.12.3    Recent Developments

8.12.4    Product Portfolio